The uplisting is obviously key. So is showing some

The uplisting is obviously key. So is showing some revenue to match some of the guidance the company has given. I don’t expect an unreasonable amount, but something to show value in from acquisitions is there. How’s Hema doing? Did that kit order we heard about get processed? What does a kit cost the customer because I read in a filing it’s a couple bucks. We heard Olaregen sold out of their first production batch, and that strong sales could be seen quickly. Is the Veneto acquisition working out? If a mso is not active awhile do they start to lose members? And most importantly I should listen to the Cc before commenting lol. I like late afternoon calls because 9:30 when people are busy at work. I’ll listen tomorrow while driving around. Joe always does good in the calls and it sounds like it went well.